Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Recruiting now

Conditions studied: Non-small Cell Lung Cancer

In brief

Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations. This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.

Key facts

Study ID

NCT06809764

Run by

Daiichi Sankyo

People needed

150

Starts

2025-02-21

Expected to finish

2027-02-12

Last updated by the study team

2025-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Shangxi Provincial Cancer Hospital — Taiyuan, China (enrolling)
• Peking University International Hospital — Beijing, China
• Beijing Cancer Hospital — Beijing, China
• Hunan Second People's Hospital — Changsha, China
• Fujian Cancer Hospital — Fuzhou, China
• Affiliated Cancer Hospital and Institute of Guangzhou Medical University — Guangzhou, China
• The First Affiliated Hospital of Sun Yat-sen University — Guangzhou, China
• Zhejiang Cancer Hospital — Hangzhou, China
• Anhui Provincial Cancer Hospital — Hefei, China
• First Affiliated Hospital of Shandong First Medical University — Jinan, China
• Cancer Hospital of Shandong First Medical University — Jinan, China
• The First Affiliated Hospital of Jinzhou Medical University — Jinzhou, China
• The First Affiliated Hospital of Nanchang University — Nanchang, China
• Guangxi Medical University Cancer Hospital — Nanning, China
• Ruijin Hospital, Shanghai Jiaotong University School Of Medicine — Shanghai, China
• Zhongshan Hospital Fudan University — Shanghai, China
• The First Hospital of China Medical University — Shenyang, China
• Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center — Shenzhen, China
• The Fourth Hospital of Hebei Medical University — Shijiazhuang, China
• The First Affiliated Hospital of Xiamen University — Xiamen, China
• Henan Cancer Hospital — Zhengzhou, China
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing, China
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.